Literature DB >> 25226528

Drug-resistant tuberculosis control in South Africa: scientific advances and health system strengthening are complementary.

Nesri Padayatchi1, Marian Loveday, Naressa Naidu.   

Abstract

We examine some aspects of the South African health system that have contributed to the current multi- and extensively drug-resistant tuberculosis (M(X)DR-TB) epidemic and identify opportunities for change and improvement. Implementation of several recent major scientific advances have the potential to accelerate the control of M(X)DR-TB, but health systems strengthening will be essential.

Entities:  

Keywords:  extensively drug-resistant tuberculosis; health systems strengthening; multi-drug-resistant tuberculosis

Mesh：

Substances：

Year:  2014        PMID： 25226528      PMCID： PMC4277040          DOI： 10.1517/14656566.2014.953053

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  9 in total

1.  Delay in commencing treatment for MDR TB at a specialised TB treatment centre in KwaZulu-Natal.

Authors:  R Narasimooloo; A Ross
Journal:  S Afr Med J       Date:  2012-05-08

2.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

Authors:  Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

3.  The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: is it patient-centred?

Authors:  M Loveday; N Padayatchi; A Voce; J Brust; K Wallengren
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

4.  Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011.

Authors:  J I Ebonwu; K S Tint; C Ihekweazu
Journal:  Int J Tuberc Lung Dis       Date:  2013-08       Impact factor: 2.373

5.  Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.

Authors:  Elize Pietersen; Elisa Ignatius; Elizabeth M Streicher; Barbara Mastrapa; Xavier Padanilam; Anil Pooran; Motasim Badri; Maia Lesosky; Paul van Helden; Frederick A Sirgel; Robin Warren; Keertan Dheda
Journal:  Lancet       Date:  2014-01-17       Impact factor: 79.321

6.  Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa.

Authors:  James C M Brust; Melissa Lygizos; Krisda Chaiyachati; Michelle Scott; Theo L van der Merwe; Anthony P Moll; Xuan Li; Marian Loveday; Sheila A Bamber; Umesh G Lalloo; Gerald H Friedland; N Sarita Shah; Neel R Gandhi
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

7.  Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.

Authors:  Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

8.  Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.

Authors:  Max R O'Donnell; Nesri Padayatchi; Charlotte Kvasnovsky; Lise Werner; Iqbal Master; C Robert Horsburgh
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

9.  What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?

Authors:  Anil Pooran; Elize Pieterson; Malika Davids; Grant Theron; Keertan Dheda
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240
  9 in total
  1 in total

1.  Rolling Out Xpert® MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems Strengthening.

Authors:  Ishani Pathmanathan; Anand Date; William L Coggin; John Nkengasong; Amy S Piatek; Heather Alexander
Journal:  Afr J Lab Med       Date:  2017-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.